Advertisement
Advertisement
U.S. markets open in 55 minutes
S&P Futures
4,170.25 +23.50 (+0.57%) Dow Futures
32,900.00 +143.00 (+0.44%) Nasdaq Futures
13,326.00 +97.25 (+0.74%) Russell 2000 Futures
1,933.10 +11.30 (+0.59%) Crude Oil
88.11 -0.90 (-1.01%) Gold
1,802.30 +11.10 (+0.62%)
Exact Sciences Corporation (EXAS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 49.37 |
| Open | 48.00 |
| Bid | 47.20 x 800 |
| Ask | 48.25 x 800 |
| Day's Range | 46.65 - 48.49 |
| 52 Week Range | 35.34 - 108.99 |
| Volume | |
| Avg. Volume | 2,132,216 |
| Market Cap | 8.326B |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.32 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.25 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Exact Sciences CorporationAnalyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.RatingFair ValueEconomic Moat5 days agoMorningstar
- TheStreet.com
Exact Sciences Goes Full Wu-Tang On Wall Street
Cancer diagnostics powerhouse Exact Sciences appears on track to easily beat full-year 2022 revenue guidance. Exact Sciences is focused on profitable growth, rather than growth for the sake of growth. Exact Sciences easily beat its own revenue guidance for the quarter.
- Barrons.com
Exact Sciences Stock Falls After Earnings. Here’s What Wall Street Is Saying.
June quarter sales were $522 million, representing 26% growth if one backs out last year's sales bump from Covid-19 tests
- Zacks
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
